's ()() chairman Gabriele Cerrone tells Proactive London's Andrew Scott why he feels its drug Foralumab is the 'crown jewel' in the company's portfolio.
It's a fully-human monoclonal anti-CD3 antibody which is being developed for treatment of inflammatory and autoimmune diseases.
Cerrone says the drug potentially addresses by far the largest markets of any of the drugs in its pipeline.
Tiziana's looking to launch Phase II trials in Crohn's Disease and MS around the end of June or early July and Cerrone says that'll put them on the path to once and for all seeing whether one of these two indications has efficacy.
''The potential turnover you can have for a monoclonal antibody is multi-billions per indication'', he says.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE